

# Melina Shoni

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/486036/publications.pdf>

Version: 2024-02-01

22  
papers

597  
citations

840776

11  
h-index

794594

19  
g-index

22  
all docs

22  
docs citations

22  
times ranked

1173  
citing authors

#	ARTICLE	IF	CITATIONS
1	Oncologic Outcomes of Surgery Versus SBRT for Non-“Small-Cell Lung Carcinoma: A Systematic Review and Meta-analysis. <i>Clinical Lung Cancer</i> , 2021, 22, e235-e292.	2.6	21
2	Oncological Outcomes of Lobar Resection, Segmentectomy, and Wedge Resection for T1a Non-“Small-Cell Lung Carcinoma: A Systematic Review and Meta-Analysis. <i>Seminars in Thoracic and Cardiovascular Surgery</i> , 2020, 32, 582-590.	0.6	33
3	Intraoperative Anesthetic Management of the Thoracic Patient. <i>Thoracic Surgery Clinics</i> , 2020, 30, 279-291.	1.0	5
4	Survival After Stereotactic Body Radiation Therapy for Clinically Diagnosed or Biopsy-Proven Early-Stage NSCLC: A Systematic Review and Meta-Analysis. <i>Journal of Thoracic Oncology</i> , 2019, 14, 583-595.	1.1	21
5	Open access phone triage for veterans with suspected malignant pleural mesothelioma. <i>Journal of Surgical Research</i> , 2017, 207, 108-114.	1.6	5
6	Benign Metastasizing Leiomyomas to the Lungs: An Institutional Case Series and a Review of the Recent Literature. <i>Annals of Thoracic Surgery</i> , 2016, 101, 253-258.	1.3	69
7	Molecular changes in endometriosis-associated ovarian clear cell carcinoma. <i>European Journal of Cancer</i> , 2015, 51, 1831-1842.	2.8	44
8	Protein Kinases and Associated Pathways in Pluripotent State and Lineage Differentiation. <i>Current Stem Cell Research and Therapy</i> , 2014, 9, 366-387.	1.3	9
9	Oncogenic mutations in cervical cancer. <i>Cancer</i> , 2013, 119, 3776-3783.	4.1	225
10	p-21-Activated kinase-1, -4 and -6 and estrogen receptor expression pattern in normal placenta and gestational trophoblastic diseases. <i>Gynecologic Oncology</i> , 2013, 131, 759-763.	1.4	3
11	BRCA1 Expression Is Epigenetically Repressed in Sporadic Ovarian Cancer Cells by Overexpression of C-Terminal Binding Protein 2. <i>Neoplasia</i> , 2013, 15, 600-IN6.	5.3	23
12	Low-grade and high-grade serous Mullerian carcinoma: Review and analysis of publicly available gene expression profiles. <i>Gynecologic Oncology</i> , 2013, 128, 488-492.	1.4	16
13	The Role of Para-Aortic Lymphadenectomy in the Surgical Staging of Women with Intermediate and High-Risk Endometrial Adenocarcinomas. <i>International Journal of Surgical Oncology</i> , 2013, 2013, 1-7.	0.6	7
14	Multiple Synchronous Primary Gynecologic Malignancies in an MSH2 Mutation Carrier With Endometriosis. <i>Journal of Clinical Oncology</i> , 2013, 31, e33-e36.	1.6	2
15	Preoperative Leukocytosis Imposes an Increased Risk of Recurrence and Death Among Patients With Nonendometrioid Endometrial Carcinoma. <i>International Journal of Gynecological Cancer</i> , 2013, 23, 312-317.	2.5	9
16	Prognostic determinants in patients with uterine and ovarian carcinosarcoma. <i>Journal of reproductive medicine, The</i> , 2013, 58, 297-304.	0.2	5
17	Aberrant activation of spleen tyrosine kinase in ovarian cancer identified through a global phosphorylation profiling of protein tyrosine kinases. <i>Gynecologic Oncology</i> , 2012, 125, S101-S102.	1.4	0
18	Can we safely omit paraaortic lymphadenectomy from the surgical staging of high-grade endometrioid, clear cell and papillary serous endometrial adenocarcinoma?. <i>Gynecologic Oncology</i> , 2012, 125, S162-S163.	1.4	0

#	ARTICLE	IF	CITATIONS
19	Changes in serum CA-125 can predict optimal cytoreduction to no gross residual disease in patients with advanced stage ovarian cancer treated with neoadjuvant chemotherapy. <i>Gynecologic Oncology</i> , 2012, 125, 362-366.	1.4	58
20	The significance of preoperative leukocytosis in endometrial carcinoma. <i>Gynecologic Oncology</i> , 2012, 125, 561-565.	1.4	22
21	Abstract 1271: Aberrant activation of Spleen Tyrosine Kinase in ovarian cancer identified through a global phosphorylation profiling of protein tyrosine kinases. , 2012, , .		0
22	Complete hydatidiform mole in women aged 40 to 49 years. <i>Journal of reproductive medicine, The</i> , 2012, 57, 254-8.	0.2	20